Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets.
Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology. 2003 Aug; 144(8):3399-405.